Security record · archived quarter
AMLX
Amylyx Pharmaceuticals, Inc. · Healthcare · Biotechnology
8Tracked holders
—Δ holders
10.16MShares held
$19.31MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 79 | +11 | 60.68M | $1.09B | +14 | −2 |
| Q1 2026 | 70 | -3 | 62.54M | $868.96M | +6 | −9 |
| Q4 2025 | 73 | 0 | 62.47M | $754.72M | — | — |
| Q3 2025 | 18 | +1 | 42.12M | $572.37M | +1 | — |
| Q2 2025 | 14 | -1 | 33.34M | $213.68M | — | −1 |
| Q1 2025 | 12 | +1 | 15.66M | $55.46M | +2 | −1 |
| Q4 2024 | 11 | 0 | 5.41M | $20.47M | +1 | −1 |
| Q3 2024 | 10 | +2 | 5.23M | $16.93M | +2 | — |
| Q2 2024 | 8 | — | 10.16M | $19.31M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | AQR Capital Management ✦ | 3.34M | — | $6.35M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | AQR Capital Management ✦ | 3.34M | — | $6.35M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | AQR Capital Management ✦ | 3.34M | — | $6.35M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 1.54M | — | $2.92M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 1.34M | — | $2.56M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 1.34M | — | $2.56M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 1.31M | — | $2.49M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 1.31M | — | $2.49M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 1.30M | — | $2.47M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 811.49K | — | $1.54M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passive) | 468.87K | — | $891,092 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 468.87K | — | $891,092 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 55.60K | — | $106,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 170 holders, 113.99M shares, $1.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API